2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
Tóm tắt
Từ khóa
Tài liệu tham khảo
2011
2011
Anderson, 2014, ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines, J Am Coll Cardiol, 63, 2304, 10.1016/j.jacc.2014.03.016
2010
Halperin, 2016, Further evolution of the ACC/AHA clinical practice guideline recommendation classification system: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, J Am Coll Cardiol, 67, 1572, 10.1016/j.jacc.2015.09.001
Jacobs, 2013, ACCF/AHA clinical practice guideline methodology summit report: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 61, 213, 10.1016/j.jacc.2012.09.025
Jacobs, 2014, The evolution and future of ACC/AHA clinical practice guidelines: a 30-year journey: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 64, 1373, 10.1016/j.jacc.2014.06.001
Yancy, 2013, 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 62, e147, 10.1016/j.jacc.2013.05.019
Packer, 2015, Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure, Circulation, 131, 54, 10.1161/CIRCULATIONAHA.114.013748
Zile, 2016, Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure, J Am Coll Cardiol, 68, 2425, 10.1016/j.jacc.2016.09.931
Solomon, 2012, The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial, Lancet, 380, 1387, 10.1016/S0140-6736(12)61227-6
Richards, 2001, Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group, J Am Coll Cardiol, 37, 1781, 10.1016/S0735-1097(01)01269-4
Tang, 2003, Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure, Circulation, 108, 2964, 10.1161/01.CIR.0000106903.98196.B6
Zaphiriou, 2005, The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study, Eur J Heart Fail, 7, 537, 10.1016/j.ejheart.2005.01.022
Son, 2012, Decision-making model for early diagnosis of congestive heart failure using rough set and decision tree approaches, J Biomed Inform, 45, 999, 10.1016/j.jbi.2012.04.013
Kelder, 2011, The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure, Circulation, 124, 2865, 10.1161/CIRCULATIONAHA.111.019216
Balion C, Don-Wauchope A, Hill S, et al. Use of Natriuretic Peptide Measurement in the Management of Heart Failure [Internet]. 13(14)-EHC118-EF ed. Rockville, MD: 2013.
Booth, 2014, Performance of BNP and NT-proBNP for diagnosis of heart failure in primary care patients: a systematic review, Heart Fail Rev, 19, 439, 10.1007/s10741-014-9445-8
Dao, 2001, Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting, J Am Coll Cardiol, 37, 379, 10.1016/S0735-1097(00)01156-6
Davis, 1994, Plasma brain natriuretic peptide in assessment of acute dyspnoea, Lancet, 343, 440, 10.1016/S0140-6736(94)92690-5
Maisel, 2002, Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure, N Engl J Med, 347, 161, 10.1056/NEJMoa020233
Moe, 2007, N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study, Circulation, 115, 3103, 10.1161/CIRCULATIONAHA.106.666255
Mueller, 2004, Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea, N Engl J Med, 350, 647, 10.1056/NEJMoa031681
van Kimmenade, 2006, Usefulness of intermediate amino-terminal pro-brain natriuretic peptide concentrations for diagnosis and prognosis of acute heart failure, Am J Cardiol, 98, 386, 10.1016/j.amjcard.2006.02.043
Januzzi, 2008, Amino-terminal pro-B-type natriuretic peptide testing for the diagnosis or exclusion of heart failure in patients with acute symptoms, Am J Cardiol, 101, 29, 10.1016/j.amjcard.2007.11.017
Santaguida, 2014, Incremental value of natriuretic peptide measurement in acute decompensated heart failure (ADHF): a systematic review, Heart Fail Rev, 19, 507, 10.1007/s10741-014-9444-9
Hill, 2014, Use of BNP and NT-proBNP for the diagnosis of heart failure in the emergency department: a systematic review of the evidence, Heart Fail Rev, 19, 421, 10.1007/s10741-014-9447-6
Costello-Boerrigter, 2006, Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction, J Am Coll Cardiol, 47, 345, 10.1016/j.jacc.2005.09.025
de Lemos, 2009, Screening the population for left ventricular hypertrophy and left ventricular systolic dysfunction using natriuretic peptides: results from the Dallas Heart Study, Am Heart J, 157, 746, 10.1016/j.ahj.2008.12.017
Goetze, 2006, Plasma pro-B-type natriuretic peptide in the general population: screening for left ventricular hypertrophy and systolic dysfunction, Eur Heart J, 27, 3004, 10.1093/eurheartj/ehl406
Ng, 2005, Community screening for left ventricular systolic dysfunction using plasma and urinary natriuretic peptides, J Am Coll Cardiol, 45, 1043, 10.1016/j.jacc.2004.12.058
Ho, 2012, Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community, J Am Coll Cardiol, 60, 1249, 10.1016/j.jacc.2012.04.053
Wang, 2012, Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study, Circulation, 126, 1596, 10.1161/CIRCULATIONAHA.112.129437
Xanthakis, 2013, Association of novel biomarkers of cardiovascular stress with left ventricular hypertrophy and dysfunction: implications for screening, J Am Heart Assoc, 2, e000399, 10.1161/JAHA.113.000399
Anwaruddin, 2006, Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study, J Am Coll Cardiol, 47, 91, 10.1016/j.jacc.2005.08.051
Redfield, 2002, Plasma brain natriuretic peptide concentration: impact of age and gender, J Am Coll Cardiol, 40, 976, 10.1016/S0735-1097(02)02059-4
Wang, 2002, Impact of age and sex on plasma natriuretic peptide levels in healthy adults, Am J Cardiol, 90, 254, 10.1016/S0002-9149(02)02464-5
Chang, 2007, Associations among androgens, estrogens, and natriuretic peptides in young women: observations from the Dallas Heart Study, J Am Coll Cardiol, 49, 109, 10.1016/j.jacc.2006.10.040
Clerico, 2012, The paradox of low BNP levels in obesity, Heart Fail Rev, 17, 81, 10.1007/s10741-011-9249-z
De Vecchis, 2014, B-type natriuretic peptide-guided versus symptom-guided therapy in outpatients with chronic heart failure: a systematic review with meta-analysis, J Cardiovasc Med (Hagerstown), 15, 122, 10.2459/JCM.0b013e328364bde1
Felker, 2009, Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials, Am Heart J, 158, 422, 10.1016/j.ahj.2009.06.018
Li, 2013, B-type natriuretic peptide-guided chronic heart failure therapy: a meta-analysis of 11 randomised controlled trials, Heart Lung Circ, 22, 852, 10.1016/j.hlc.2013.03.077
Porapakkham, 2010, B-type natriuretic peptide-guided heart failure therapy: a meta-analysis, Arch Intern Med, 170, 507, 10.1001/archinternmed.2010.35
Savarese, 2013, Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials, PLoS One, 8, e58287, 10.1371/journal.pone.0058287
Troughton, 2014, Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis, Eur Heart J, 35, 1559, 10.1093/eurheartj/ehu090
Xin, 2015, Does B-type natriuretic peptide-guided therapy improve outcomes in patients with chronic heart failure? A systematic review and meta-analysis of randomized controlled trials, Heart Fail Rev, 20, 69, 10.1007/s10741-014-9437-8
Berger, 2010, N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure: a 3-arm, prospective, randomized pilot study, J Am Coll Cardiol, 55, 645, 10.1016/j.jacc.2009.08.078
Gaggin, 2012, Heart failure outcomes and benefits of NT-proBNP-guided management in the elderly: results from the prospective, randomized ProBNP outpatient tailored chronic heart failure therapy (PROTECT) study, J Card Fail, 18, 626, 10.1016/j.cardfail.2012.05.005
Jourdain, 2007, Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study, J Am Coll Cardiol, 49, 1733, 10.1016/j.jacc.2006.10.081
Karlstrom, 2011, Brain natriuretic peptide-guided treatment does not improve morbidity and mortality in extensively treated patients with chronic heart failure: responders to treatment have a significantly better outcome, Eur J Heart Fail, 13, 1096, 10.1093/eurjhf/hfr078
Lainchbury, 2009, N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial, J Am Coll Cardiol, 55, 53, 10.1016/j.jacc.2009.02.095
Persson, 2010, Improved pharmacological therapy of chronic heart failure in primary care: a randomized Study of NT-proBNP Guided Management of Heart Failure–SIGNAL-HF (Swedish Intervention study–Guidelines and NT-proBNP AnaLysis in Heart Failure), Eur J Heart Fail, 12, 1300, 10.1093/eurjhf/hfq169
Pfisterer, 2009, BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial, JAMA, 301, 383, 10.1001/jama.2009.2
Shah, 2011, The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure, J Card Fail, 17, 613, 10.1016/j.cardfail.2011.04.012
Troughton, 2000, Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations, Lancet, 355, 1126, 10.1016/S0140-6736(00)02060-2
Singer, 2009, Rapid Emergency Department Heart Failure Outpatients Trial (REDHOT II): a randomized controlled trial of the effect of serial B-type natriuretic peptide testing on patient management, Circ Heart Fail, 2, 287, 10.1161/CIRCHEARTFAILURE.108.826685
Stienen, 2014, Rationale and design of PRIMA II: A multicenter, randomized clinical trial to study the impact of in-hospital guidance for acute decompensated heart failure treatment by a predefined NT-PRoBNP target on the reduction of readmIssion and Mortality rAtes, Am Heart J, 168, 30, 10.1016/j.ahj.2014.04.008
Stienen, 2016, PRIMA II: can NT-pro-brain-natriuretic peptide (NT-proBNP) guided therapy during admission for acute heart failure reduce mortality and readmissions?, J Card Fail, 22, 939, 10.1016/j.cardfail.2016.09.011
Kociol, 2010, Troponin elevation in heart failure prevalence, mechanisms, and clinical implications, J Am Coll Cardiol, 56, 1071, 10.1016/j.jacc.2010.06.016
Amsterdam, 2014, 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 64, e139, 10.1016/j.jacc.2014.09.017
Masson, 2012, Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials, Circulation, 125, 280, 10.1161/CIRCULATIONAHA.111.044149
Savarese, 2014, Changes of natriuretic peptides predict hospital admissions in patients with chronic heart failure: a meta-analysis, J Am Coll Cardiol HF, 2, 148
de Lemos, 2013, Increasingly sensitive assays for cardiac troponins: a review, JAMA, 309, 2262, 10.1001/jama.2013.5809
de Boer, 2015, State of the Art: Newer biomarkers in heart failure, Eur J Heart Fail, 17, 559, 10.1002/ejhf.273
Gopal, 2013, New and emerging biomarkers in left ventricular systolic dysfunction–insight into dilated cardiomyopathy, J Cardiovasc Transl Res, 6, 516, 10.1007/s12265-013-9462-3
O'Meara, 2013, Circulating biomarkers in patients with heart failure and preserved ejection fraction, Curr Heart Fail Rep, 10, 350, 10.1007/s11897-013-0160-x
Karayannis, 2013, The emerging role of Galectin-3 and ST2 in heart failure: practical considerations and pitfalls using novel biomarkers, Curr Heart Fail Rep, 10, 441, 10.1007/s11897-013-0169-1
Ahmad, 2014, Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure, J Am Coll Cardiol HF, 2, 260
Bayes-Genis, 2014, Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3, J Am Coll Cardiol, 63, 158, 10.1016/j.jacc.2013.07.087
Gaggin, 2014, Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure, J Am Coll Cardiol HF, 2, 65
Ky, 2012, Multiple biomarkers for risk prediction in chronic heart failure, Circ Heart Fail, 5, 183, 10.1161/CIRCHEARTFAILURE.111.965020
Sabatine, 2012, Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease, Circulation, 125, 233, 10.1161/CIRCULATIONAHA.111.063842
Ahmad, 2014, Charting a roadmap for heart failure biomarker studies, J Am Coll Cardiol HF, 2, 477
Miller, 2012, Serial measurements of midregion proANP and copeptin in ambulatory patients with heart failure: incremental prognostic value of novel biomarkers in heart failure, Heart, 98, 389, 10.1136/heartjnl-2011-300823
Creemers, 2012, Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease?, Circ Res, 110, 483, 10.1161/CIRCRESAHA.111.247452
Wong, 2015, Circulating microRNAs in heart failure with reduced and preserved left ventricular ejection fraction, Eur J Heart Fail, 17, 393, 10.1002/ejhf.223
Ovchinnikova, 2016, Signature of circulating microRNAs in patients with acute heart failure, Eur J Heart Fail, 18, 414, 10.1002/ejhf.332
Shah, 2012, Metabolomic profiling for the identification of novel biomarkers and mechanisms related to common cardiovascular diseases: form and function, Circulation, 126, 1110, 10.1161/CIRCULATIONAHA.111.060368
Cheng, 2015, Metabolic disturbances identified in plasma are associated with outcomes in patients with heart failure: diagnostic and prognostic value of metabolomics, J Am Coll Cardiol, 65, 1509, 10.1016/j.jacc.2015.02.018
Zheng, 2013, Associations between metabolomic compounds and incident heart failure among African Americans: the ARIC Study, Am J Epidemiol, 178, 534, 10.1093/aje/kwt004
Ledwidge, 2013, Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial, JAMA, 310, 66, 10.1001/jama.2013.7588
Huelsmann, 2013, PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial, J Am Coll Cardiol, 62, 1365, 10.1016/j.jacc.2013.05.069
Anand, 2003, Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT), Circulation, 107, 1278, 10.1161/01.CIR.0000054164.99881.00
Berger, 2002, B-type natriuretic peptide predicts sudden death in patients with chronic heart failure, Circulation, 105, 2392, 10.1161/01.CIR.0000016642.15031.34
Forfia, 2005, Relationship between B-type natriuretic peptides and pulmonary capillary wedge pressure in the intensive care unit, J Am Coll Cardiol, 45, 1667, 10.1016/j.jacc.2005.01.046
Maeda, 2000, High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure, J Am Coll Cardiol, 36, 1587, 10.1016/S0735-1097(00)00912-8
Neuhold, 2008, Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease, J Am Coll Cardiol, 52, 266, 10.1016/j.jacc.2008.03.050
Taub, 2009, Usefulness of B-type natriuretic peptide levels in predicting hemodynamic and clinical decompensation, Heart Fail Clin, 5, 169, 10.1016/j.hfc.2008.11.009
Bettencourt, 2004, N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients, Circulation, 110, 2168, 10.1161/01.CIR.0000144310.04433.BE
Cheng, 2001, A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study, J Am Coll Cardiol, 37, 386, 10.1016/S0735-1097(00)01157-8
Fonarow, 2008, Usefulness of B-type natriuretic peptide and cardiac troponin levels to predict in-hospital mortality from ADHERE, Am J Cardiol, 101, 231, 10.1016/j.amjcard.2007.07.066
Logeart, 2004, Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure, J Am Coll Cardiol, 43, 635, 10.1016/j.jacc.2003.09.044
Maisel, 2004, Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath, J Am Coll Cardiol, 44, 1328, 10.1016/j.jacc.2004.06.015
Zairis, 2010, Multimarker strategy for the prediction of 31 days cardiac death in patients with acutely decompensated chronic heart failure, Int J Cardiol, 141, 284, 10.1016/j.ijcard.2008.12.017
Peacock, 2008, Cardiac troponin and outcome in acute heart failure, N Engl J Med, 358, 2117, 10.1056/NEJMoa0706824
Lee, 2012, Prediction of heart failure mortality in emergent care: a cohort study, Ann Intern Med, 156, 767, 10.7326/0003-4819-156-11-201206050-00003
Santaguida, 2014, BNP and NT-proBNP as prognostic markers in persons with acute decompensated heart failure: a systematic review, Heart Fail Rev, 19, 453, 10.1007/s10741-014-9442-y
Horwich, 2003, Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure, Circulation, 108, 833, 10.1161/01.CIR.0000084543.79097.34
Ilva, 2008, Clinical significance of cardiac troponins I and T in acute heart failure, Eur J Heart Fail, 10, 772, 10.1016/j.ejheart.2008.06.009
Dhaliwal, 2009, Reduction in BNP levels with treatment of decompensated heart failure and future clinical events, J Card Fail, 15, 293, 10.1016/j.cardfail.2008.11.007
O'Connor, 2010, Triage after hospitalization with advanced heart failure: the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) risk model and discharge score, J Am Coll Cardiol, 55, 872, 10.1016/j.jacc.2009.08.083
O'Brien, 2003, Pre-discharge, but not admission, levels of NT-proBNP predict adverse prognosis following acute LVF, Eur J Heart Fail, 5, 499, 10.1016/S1388-9842(03)00098-9
Cohen-Solal, 2009, Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure, J Am Coll Cardiol, 53, 2343, 10.1016/j.jacc.2009.02.058
Salah, 2014, A novel discharge risk model for patients hospitalised for acute decompensated heart failure incorporating N-terminal pro-B-type natriuretic peptide levels: a European coLlaboration on Acute decompeNsated Heart Failure: ELAN-HF Score, Heart, 100, 115, 10.1136/heartjnl-2013-303632
Flint, 2014, B-type natriuretic peptide predicts 30-day readmission for heart failure but not readmission for other causes, J Am Heart Assoc, 3, e000806, 10.1161/JAHA.114.000806
Kociol, 2011, Admission, discharge, or change in B-type natriuretic peptide and long-term outcomes: data from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) linked to Medicare claims, Circ Heart Fail, 4, 628, 10.1161/CIRCHEARTFAILURE.111.962290
Kociol, 2013, Markers of decongestion, dyspnea relief, and clinical outcomes among patients hospitalized with acute heart failure, Circ Heart Fail, 6, 240, 10.1161/CIRCHEARTFAILURE.112.969246
Verdiani, 2008, NT-ProBNP reduction percentage during hospital stay predicts long-term mortality and readmission in heart failure patients, J Cardiovasc Med (Hagerstown), 9, 694, 10.2459/JCM.0b013e3282f447ae
Bayes-Genis, 2005, NT-ProBNP reduction percentage during admission for acutely decompensated heart failure predicts long-term cardiovascular mortality, J Card Fail, 11, S3, 10.1016/j.cardfail.2005.04.006
Alonso-Martinez, 2002, C-reactive protein as a predictor of improvement and readmission in heart failure, Eur J Heart Fail, 4, 331, 10.1016/S1388-9842(02)00021-1
Dieplinger, 2010, Prognostic value of established and novel biomarkers in patients with shortness of breath attending an emergency department, Clin Biochem, 43, 714, 10.1016/j.clinbiochem.2010.02.002
Januzzi, 2007, Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study, J Am Coll Cardiol, 50, 607, 10.1016/j.jacc.2007.05.014
Manzano-Fernandez, 2011, Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction, Am J Cardiol, 107, 259, 10.1016/j.amjcard.2010.09.011
Rehman, 2008, Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure, J Am Coll Cardiol, 52, 1458, 10.1016/j.jacc.2008.07.042
Shah, 2010, Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure, Eur J Heart Fail, 12, 826, 10.1093/eurjhf/hfq091
de Boer, 2011, Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction, Ann Med, 43, 60, 10.3109/07853890.2010.538080
Lok, 2010, Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study, Clin Res Cardiol, 99, 323, 10.1007/s00392-010-0125-y
Tang, 2011, Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival, Am J Cardiol, 108, 385, 10.1016/j.amjcard.2011.03.056
Tang, 2016, Prognostic Value of Baseline and Changes in Circulating Soluble ST2 Levels and the Effects of Nesiritide in Acute Decompensated Heart Failure, J Am Coll Cardiol HF, 4, 68
Januzzi, 2015, ST2 and prognosis in acutely decompensated heart failure: the International ST2 Consensus Panel, Am J Cardiol, 115, 26B, 10.1016/j.amjcard.2015.01.037
Mebazaa, 2015, ST2 and multimarker testing in acute decompensated heart failure, Am J Cardiol, 115, 38B, 10.1016/j.amjcard.2015.01.039
Fermann, 2012, Galectin 3 complements BNP in risk stratification in acute heart failure, Biomarkers, 17, 706, 10.3109/1354750X.2012.719037
Lassus, 2013, Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: the Multinational Observational Cohort on Acute Heart Failure (MOCA) study, Int J Cardiol, 168, 2186, 10.1016/j.ijcard.2013.01.228
1987, Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group, N Engl J Med, 316, 1429
1991, Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators, N Engl J Med, 325, 293, 10.1056/NEJM199108013250501
Packer, 1999, Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group, Circulation, 100, 2312, 10.1161/01.CIR.100.23.2312
Pfeffer, 1992, Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. The SAVE Investigators, N Engl J Med, 327, 669, 10.1056/NEJM199209033271001
1993, Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators, Lancet, 342, 821
Kober, 1995, A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group, N Engl J Med, 333, 1670, 10.1056/NEJM199512213332503
Cohn, 2001, A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure, N Engl J Med, 345, 1667, 10.1056/NEJMoa010713
Pfeffer, 2003, Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both, N Engl J Med, 349, 1893, 10.1056/NEJMoa032292
Konstam, 2009, Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial, Lancet, 374, 1840, 10.1016/S0140-6736(09)61913-9
Pfeffer, 2003, Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme, Lancet, 362, 759, 10.1016/S0140-6736(03)14282-1
McMurray, 2014, Angiotensin-neprilysin inhibition versus enalapril in heart failure, N Engl J Med, 371, 993, 10.1056/NEJMoa1409077
1999, Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF), Lancet, 353, 2001, 10.1016/S0140-6736(99)04440-2
Packer, 2002, Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study, Circulation, 106, 2194, 10.1161/01.CIR.0000035653.72855.BF
Eschalier, 2013, Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure), J Am Coll Cardiol, 62, 1585, 10.1016/j.jacc.2013.04.086
Pitt, 1999, The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators, N Engl J Med, 341, 709, 10.1056/NEJM199909023411001
Garg, 1995, Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials, JAMA, 273, 1450, 10.1001/jama.1995.03520420066040
Woodard-Grice, 2010, Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema, Pharmacogenet Genomics, 20, 532, 10.1097/FPC.0b013e32833d3acb
Yusuf, 2008, Telmisartan, ramipril, or both in patients at high risk for vascular events, N Engl J Med, 358, 1547, 10.1056/NEJMoa0801317
Yusuf, 2008, Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial, Lancet, 372, 1174, 10.1016/S0140-6736(08)61242-8
2015
Packer, 2002, Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE), Circulation, 106, 920, 10.1161/01.CIR.0000029801.86489.50
Kostis, 2004, Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial, Am J Hypertens, 17, 103, 10.1016/j.amjhyper.2003.09.014
Vardeny, 2014, Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure, J Am Coll Cardiol HF, 2, 663
Messerli, 2000, Vasopeptidase inhibition and angio-oedema, Lancet, 356, 608, 10.1016/S0140-6736(00)02596-4
Braunwald, 2015, The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure, J Am Coll Cardiol, 65, 1029, 10.1016/j.jacc.2015.01.033
Ruilope, 2010, Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study, Lancet, 375, 1255, 10.1016/S0140-6736(09)61966-8
Bohm, 2015, Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT Trial), Am J Cardiol, 116, 1890, 10.1016/j.amjcard.2015.09.029
Swedberg, 2010, Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study, Lancet, 376, 875, 10.1016/S0140-6736(10)61198-1
Fox, 2014, Ivabradine in stable coronary artery disease without clinical heart failure, N Engl J Med, 371, 1091, 10.1056/NEJMoa1406430
Fox, 2008, Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial, Lancet, 372, 807, 10.1016/S0140-6736(08)61170-8
Pitt, 1997, Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE), Lancet, 349, 747, 10.1016/S0140-6736(97)01187-2
Pitt, 2003, Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction, N Engl J Med, 348, 1309, 10.1056/NEJMoa030207
Authors, 1999, The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial, Lancet, 353, 9, 10.1016/S0140-6736(98)11181-9
Packer, 2001, Effect of carvedilol on survival in severe chronic heart failure, N Engl J Med, 344, 1651, 10.1056/NEJM200105313442201
Taylor, 2004, Combination of isosorbide dinitrate and hydralazine in blacks with heart failure, N Engl J Med, 351, 2049, 10.1056/NEJMoa042934
Cohn, 1986, Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study, N Engl J Med, 314, 1547, 10.1056/NEJM198606123142404
Chobanian, 2003, Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, Hypertension, 42, 1206, 10.1161/01.HYP.0000107251.49515.c2
Levy, 1996, The progression from hypertension to congestive heart failure, JAMA, 275, 1557, 10.1001/jama.1996.03530440037034
Pitt, 2014, Spironolactone for heart failure with preserved ejection fraction, N Engl J Med, 370, 1383, 10.1056/NEJMoa1313731
Pfeffer, 2015, Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial, Circulation, 131, 34, 10.1161/CIRCULATIONAHA.114.013255
Edelmann, 2013, Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial, JAMA, 309, 781, 10.1001/jama.2013.905
Yusuf, 2003, Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial, Lancet, 362, 777, 10.1016/S0140-6736(03)14285-7
Massie, 2008, Irbesartan in patients with heart failure and preserved ejection fraction, N Engl J Med, 359, 2456, 10.1056/NEJMoa0805450
Redfield, 2015, Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction, N Engl J Med, 373, 2314, 10.1056/NEJMoa1510774
Redfield, 2013, Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial, JAMA, 309, 1268, 10.1001/jama.2013.2024
Anker, 2009, Ferric carboxymaltose in patients with heart failure and iron deficiency, N Engl J Med, 361, 2436, 10.1056/NEJMoa0908355
Ponikowski, 2015, Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency, Eur Heart J, 36, 657, 10.1093/eurheartj/ehu385
Kapoor, 2013, Outcomes of patients with chronic heart failure and iron deficiency treated with intravenous iron: a meta-analysis. Cardiovasc Hematol Disord, Drug Targets, 13, 35
Swedberg, 2013, Treatment of anemia with darbepoetin alfa in systolic heart failure, N Engl J Med, 368, 1210, 10.1056/NEJMoa1214865
Cleland, 2005, Once-monthly administration of darbepoetin alfa for the treatment of patients with chronic heart failure and anemia: a pharmacokinetic and pharmacodynamic investigation, J Cardiovasc Pharmacol, 46, 155, 10.1097/01.fjc.0000167013.77092.c4
Klapholz, 2009, The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure, Eur J Heart Fail, 11, 1071, 10.1093/eurjhf/hfp130
Ponikowski, 2007, Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial, J Am Coll Cardiol, 49, 753, 10.1016/j.jacc.2006.11.024
Silverberg, 2001, The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study, J Am Coll Cardiol, 37, 1775, 10.1016/S0735-1097(01)01248-7
van der Meer, 2009, Erythropoietin treatment in patients with chronic heart failure: a meta-analysis, Heart, 95, 1309, 10.1136/hrt.2008.161091
van Veldhuisen, 2007, Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia, Eur Heart J, 28, 2208, 10.1093/eurheartj/ehm328
Ghali, 2008, Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia, Circulation, 117, 526, 10.1161/CIRCULATIONAHA.107.698514
Kotecha, 2011, Erythropoietin as a treatment of anemia in heart failure: systematic review of randomized trials, Am Heart J, 161, 822, 10.1016/j.ahj.2011.02.013
Bennett, 2008, Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia, JAMA, 299, 914, 10.1001/jama.299.8.914
Bohlius, 2006, Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients, J Natl Cancer Inst, 98, 708, 10.1093/jnci/djj189
Pfeffer, 2009, A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease, N Engl J Med, 361, 2019, 10.1056/NEJMoa0907845
Szczech, 2008, Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes, Kidney Int, 74, 791, 10.1038/ki.2008.295
Xie, 2016, Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis, Lancet, 387, 435, 10.1016/S0140-6736(15)00805-3
Thomopoulos, 2016, Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels - updated overview and meta-analyses of randomized trials, J Hypertens, 34, 613, 10.1097/HJH.0000000000000881
Wright, 2015, A Randomized Trial of Intensive versus Standard Blood-Pressure Control, N Engl J Med, 373, 2103, 10.1056/NEJMoa1511939
Williamson, 2016, Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged >/=75 years: A randomized clinical trial, JAMA, 315, 2673, 10.1001/jama.2016.7050
Lv, 2013, Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis, CMAJ, 185, 949, 10.1503/cmaj.121468
Deleted in press.
Law, 2009, Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies, BMJ, 338, b1665, 10.1136/bmj.b1665
van Veldhuisen, 2009, Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure), J Am Coll Cardiol, 53, 2150, 10.1016/j.jacc.2009.02.046
Piller, 2011, Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT), Circulation, 124, 1811, 10.1161/CIRCULATIONAHA.110.012575
Bradley, 2005, Continuous positive airway pressure for central sleep apnea and heart failure, N Engl J Med, 353, 2025, 10.1056/NEJMoa051001
MacDonald, 2008, The current prevalence of sleep disordered breathing in congestive heart failure patients treated with beta-blockers, J Clin Sleep Med, 4, 38, 10.5664/jcsm.27076
Cowie, 2015, Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure, N Engl J Med, 373, 1095, 10.1056/NEJMoa1506459
McEvoy, 2016, CPAP for prevention of cardiovascular events in obstructive sleep apnea, N Engl J Med, 375, 919, 10.1056/NEJMoa1606599